Moleculin Biotech, Inc.
MBRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001659617
In the last 90 days, Moleculin Biotech, Inc. insiders filed 3 open-market purchases and 0 sales; 18 institutions reported holding it in 13F filings for Q2 2026, worth $518.5K in total; no superinvestor holds it.
Q2 2026 vs. Q1 2026
How the institutions holding Moleculin Biotech, Inc. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Q2 2026 | Change |
|---|---|---|---|
| Holders | 20 | 18 | −2 |
| Shares | 152.1K | 185.8K | +33.7K (+22.1%) |
| Value | $347.9K | $518.5K | +$170.6K (+49.0%) |
New holders (5)
Institutions that held Moleculin Biotech, Inc. at the end of Q2 2026 but not at the end of Q1 2026.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| XTX Topco Ltd | 22,942 | $64.0K | 0.00% |
| Citigroup Inc | 2,674 | $7.46K | 0.00% |
| Barclays PLC | 621 | $1.73K | 0.00% |
| Jones Financial Companies LLLP | 360 | $1.18K | 0.00% |
| Wells Fargo & Company | 200 | $558 | 0.00% |
Sold out (7)
Institutions that held Moleculin Biotech, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Sabby Management, LLC | 75,021 | $171.8K |
| HRT Financial LP | 13,739 | $31.0K |
| UBS Group AG | 3,409 | $7.81K |
| Pinnacle Wealth Planning Services, Inc. | 281 | $643 |
| Vanguard Global Advisers, LLC | 24 | $55 |
| FMR LLC | 3 | $7 |
| Caitong International Asset Management Co., Ltd | 2 | $5 |